Live Quote · NASDAQGPCRHealthcare · Biotechnology

Structure Therapeutics Inc.

$53.45▲ 2.55%(+$1.33)

TickerSpark Score

57/100

▌ Mixed

80

Valuation

20

Profitability

20

Growth

84

Health

80

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GPCR research report →

52-Week Range48% of range

Low

$15.80

Current

$53.45

High

$94.90

Company Overviewstructuretx.com

About the company

Structure Therapeutics Inc. , an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R).

CEO: Raymond C. Stevens
IPO: 2023
Employees: 163
HQ: South San Francisco, CA, US

Price Chart

+161.50% · this period

Valuation

Market Cap: $3.08B
P/E: -20.25
P/S: 0.00
P/B: 2.68
EV/EBITDA: -16.49
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -15.14%
ROIC: -14.44%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-141,202,000 · -15.24%
EPS: $-2.40 · -2.56%
Op Income: $-287,567,533
FCF YoY: -91.49%

Performance & Tape

52W High: $94.90
52W Low: $15.80
50D MA: $42.29
200D MA: $49.52
Beta: -1.42
Avg Volume: 851.99K

Get TickerSpark's AI analysis on GPCR

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jun 25, 26	Lin Xichen	officer: CHIEF SCIENTIFIC OFFICER	other	23,634	$8.04K
Jun 25, 26	Lin Xichen	officer: CHIEF SCIENTIFIC OFFICER	other	23,634	$0
Jun 25, 26	Lin Xichen	officer: CHIEF SCIENTIFIC OFFICER	other	23,634	$8.04K
Jun 25, 26	Lin Xichen	officer: CHIEF SCIENTIFIC OFFICER	other	7,878	$0
Jun 25, 26	Lin Xichen	officer: CHIEF SCIENTIFIC OFFICER	sell	7,878	$0
Jun 17, 26	Russell Angus C.	director	other	39,453	$591.79K
Jun 17, 26	LOVE TED W	director	other	39,453	$591.79K
Jun 17, 26	Waldstreicher Joanne	director	other	39,453	$591.79K
Jun 17, 26	DOBMEIER ERIC	director	other	39,453	$591.79K
Jun 17, 26	TETLOW SHARON	director	other	39,453	$591.79K

Coverage · GPCR

Our GPCR coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Should You Buy the Palatin Technologies IPO? Here's the Setup

Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.